SWOG clinical trial number
S1706

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

53% Accrual
Accrual
53%
Closed
Phase
53% Accrual
Accrual
53%
Abbreviated Title
Phase II Rando, Double Blind Placebo/Veliparib + RT for Inflammatory Breast
Status Notes
Permanently Closed to Accrual 07/01/2024, 2:00 pm CT
Activated
09/12/2018
Closed
07/01/2024
Participants
ALLIANCE, ECOG-ACRIN, NRG

Research committees

Breast Cancer

Treatment

Radiation Therapy Olaparib RT

Other Clinical Trials

CTSU-A012301
SWOG Clinical Trial Number
S2212
SWOG Clinical Trial Number
Research Committee(s)
Breast Cancer
Activated
07/21/2023
31% Accrual
Accrual
31%
Open
Phase